Stockscreener 앱 받기
1.419
5.22%
0.079
전일 마감가:
$1.34
열려 있는:
$1.36
하루 거래량:
340.56K
Relative Volume:
0.53
시가총액:
$21.60M
수익:
$486.00K
순이익/손실:
$-28.43M
주가수익비율:
-0.5034
EPS:
-2.8189
순현금흐름:
$-26.75M
1주 성능:
+21.55%
1개월 성능:
+2.92%
6개월 성능:
-48.91%
1년 성능:
-32.86%
1일 변동 폭
$1.2961
$1.4607
1주일 범위
$1.10
$1.49
52주 변동 폭
$0.85
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
명칭
Vyne Therapeutics Inc
전화
800-775-7936
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
VYNE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.42 | 24.16M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.44 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.05 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
592.02 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.22 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | BTIG Research | Buy |
| 2021-12-06 | 재개 | H.C. Wainwright | Buy |
Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스
What drives VYNE Therapeutics Inc. stock priceOutperformance with explosive growth - PrintWeekIndia
Is VYNE Therapeutics Inc. a good long term investmentUnrivaled growth potential - PrintWeekIndia
VYNE Therapeutics Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
What analysts say about VYNE Therapeutics Inc. stockExponentially increasing returns - jammulinksnews.com
Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser
How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN
VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World
VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times
BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada
H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada
NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times
FDA partially lifts clinical hold on VYNE’s VYN202 psoriasis trial By Investing.com - Investing.com UK
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq
Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times
Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World
Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa
VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India
VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World
Vyne Therapeutics Inc (VYNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.74%
0.00%
자본화:
|
볼륨(24시간):